# Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso

> **NCT01577771** · PHASE4 · COMPLETED · sponsor: **Agence de Médecine Préventive, France** · enrollment: 663 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Prevnar13 (manufactured by Pfizer)

## Key facts

- **NCT ID:** NCT01577771
- **Lead sponsor:** Agence de Médecine Préventive, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 663 (ACTUAL)
- **Last updated:** 2017-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577771, "Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01577771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*